LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation

Hypertension

Volumn 50, Issue 6, 2007, Pages 1049-1056

  Ruiz Hurtado, Gema ^a   Fernández Velasco, María ^a   Mourelle, Marisabel ^b   Delgado, Carmen ^a  

^a Instituto Nacional de Toxicologia   (Spain)

^b Lacer SA   (Spain)

Author keywords

Cardiac hypertrophy; Caveolin 3; cGMP; eNOS; Hsp90; NO

Indexed keywords

CAVEOLIN 3; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEAT SHOCK PROTEIN 90; LA 419; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPERTENSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BLOOD PRESSURE; CAVEOLIN 3; CYCLIC GMP; FIBROSIS; HSP90 HEAT-SHOCK PROTEINS; HYPERTROPHY, LEFT VENTRICULAR; ISOSORBIDE DINITRATE; MALE; MYOCARDIUM; NITRIC OXIDE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR REMODELING;

EID: 36448954982     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.093666     Document Type: Article

References (32)

1. Brown DW, Giles WH, Croft JB. Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J. 2000;140:848-856.
2. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
3. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation. 2000;102:470-479.
4. Burlew BS, Weber KT. Connective tissue and the heart. Functional significance and regulatory mechanisms. Cardiol Clin. 2000;18:435-442.
5. Paulus WJ. The role of nitric oxide in the failing heart. Heart Fail Rev. 2001;6:105-118.
6. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818.
7. Cheng TH, Shih NL, Chen SY, Lin JW, Chen YL, Chen CH, Lin H, Cheng CF, Chiu WT, Wang DL, Chen JJ. Nitric oxide inhibits endothelin-1-induced cardiomyocyte hypertrophy through cGMP-mediated suppression of extracellular-signal regulated kinase phosphorylation. Mol Pharmacol. 2005;68:1183-1192.
8. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation. 1999;99:2396-2401.
9. Rassaf T, Poll LW, Brouzos P, Lauer T, Totzeck M, Kleinbongard P, Gharini P, Andersen K, Schulz R, Heusch G, Modder U, Kelm M. Positive effects of nitric oxide on left ventricular function in humans. Eur Heart J. 2006;27:1699-1705.
10. Hernandez MR, Tonda R, Arderiu G, Pino M, Serradell M, Escolar G. Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis. Eur J Clin Invest. 2005;35:337-342.
11. Vilahur G, Pena E, Padro T, Badimon L. Protein disulphide isomerase-mediated LA419-NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Thromb Haemost. 2007;97:650-657.
12. Vilahur G, Segales E, Casani L, Badimon L. A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb Haemost. 2004;91:1035-1043.
13. Fernandez-Velasco M, Ruiz-Hurtado G, Delgado C. I k1 and I f in ventricular myocytes isolated from control and hypertrophied rat hearts. Pflugers Arch. 2006;452:146-154.
14. Martinez-Murillo R, Fernandez AP, Serrano J, Rodrigo J, Salas E, Mourelle M, Martinez A. The nitric oxide donor LA 419 decreases brain damage in a focal ischemia model. Neurosci Lett. 2007;415:149-153.
15. Song KS, Li S, Okamoto T, Quilliam LA, Sargiacomo M, Lisanti MP. Co-purification and direct interaction of ras with caveolin, an integral membrane protein of caveolae microdomains. J Biol Chem. 1996;271:9690-9697.
16. Kempf T, Wollert KC. Nitric oxide and the enigma of cardiac hypertrophy. Bioessays. 2004;26:608-615.
17. Grieve DJ, MacCarthy PA, Gall NP, Cave AC, Shah AM. Divergent biological actions of coronary endothelial nitric oxide during progression of cardiac hypertrophy. Hypertension. 2001;38:267-273.
18. Piech A, Dessy C, Havaux X, Feron O, Balligand J-L. Differential regulation of nitric oxide synthases and their allosteric regulators in heart and vessels of hypertensive rats. Cardiovasc Res. 2003;57:456-467.
19. Janssens S, Pokreisz P, Schoonjans L, Pellens M, Vermeersch P, Tjwa M, Jans P, Scherrer-Crosbie M, Picard MH, Szelid Z, Gillijns H, Van de Werf F, Collen D, Bloch KD. Cardiomyocyte-specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res. 2004;94:1256-1262.
20. Ruetten H, Dimmeler S, Gehring D, Ihling C, Zeiher AM. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res. 2005;66:444-453.
21. Wenzel S, Rohde C, Wingerning S, Roth J, Kojda G, Schluter KD. Lack of endothelial nitric oxide synthase-derived nitric oxide formation favors hypertrophy in adult ventricular cardiomyocytes. Hypertension. 2007;49:193-200.
22. Zhou J, Ando H, Macova M, Dou J, Saavedra JM. Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab. 2005;25:878-886.
23. Li PG, Xu JW, Ikeda K, Kobayakawa A, Kayano Y, Mitani T, Ikami T, Yamori Y. Caffeic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2005;28:369-377.
24. Diez J. Profibrotic effects of angiotensin II in the heart: a matter of mediators. Hypertension. 2004;43:1164-1165.
25. Zahabi A, Picard S, Fortin N, Reudelhuber TL, Deschepper CF. Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J Biol Chem. 2003;278:47694-47699.
26. Le Lay S, Kurzchalia TV. Getting rid of caveolins: Phenotypes of caveolin-deficient animals. Biochim Biophys Acta. 2005;1746:322-333.
27. Ratajczak P, Damy T, Heymes C, Oliviero P, Marotte F, Robidel E, Sercombe R, Boczkowski J, Rappaport L, Samuel JL. Caveolin-1 and -3 dissociations from caveolae to cytosol in the heart during aging and after myocardial infarction in rat. Cardiovasc Res. 2003;57:358-369.
28. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res. 2006;69:788-797.
29. Kikuchi T, Oka N, Koga A, Miyazaki H, Ohmura H, Imaizumi T. Behavior of caveolae and caveolin-3 during the development of myocyte hypertrophy. J Cardiovasc Pharmacol. 2005;45:204-210.
30. Piech A, Massart PE, Dessy C, Feron O, Havaux X, Morel N, Vanoverschelde JL, Donckier J, Balligand JL. Decreased expression of myocardial eNOS and caveolin in dogs with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 2002;282:H219-H231.
31. Woodman SE, Park DS, Cohen AW, Cheung MW-C, Chandra M, Shirani J, Tang B, Jelicks LA, Kitsis RN, Christ GJ, Factor SM, Tanowitz HB, Lisanti MP. Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade. J Biol Chem. 2002;277:38988-38997.
32. Lácer. Derivates of isosorbide mononitrate as vasodilator agents with reduced tolerance. WO Patent. 2005;0020420.